

# **Procurement of second-line drugs and estimation of needs for the new project**

**Fuad Mirzayev**

**WHO, GLC Secretariat**


**Second MDR-TB Consultant Course**

**13-17 November 2006, Riga, Latvia**




**World Health  
Organization**

# GLC model



# GLC approved countries/projects as of September 2006



# GLC approved countries

**Total: 40 countries – 22 working with GFATM**

## GFATM support

- Azerbaijan
- Bangladesh
- Bolivia
- DR Congo
- Dominican Republic
- Ecuador
- Egypt
- Georgia
- Honduras
- Kenya
- Kyrgyzstan
- Mongolia
- Moldova
- Nicaragua
- Peru
- Philippines
- Paraguay
- Romania
- Russia
- El Salvador
- Timor-Leste
- Uzbekistan

## Domestic or other donor support

- Armenia
- Belize
- Burkina Faso
- Costa Rica
- Estonia
- Guinea
- Haiti
- India
- Jordan
- Cambodia
- Lebanon
- Lithuania
- Latvia
- Mexico
- Nepal
- Rwanda
- Syria
- Tunisia

## GLC applications under review

- 6 regions in Russian Federation (GFATM)
- China (GFATM)
- Kazakhstan (non GFATM)
- Uganda (non GFATM)
- India (both GFATM, other donors and domestic resources)

**= More than 23,000 MDR-TB patients**

# Procurement cycle

## WHO

- Prequalification project
- GMP standard
- Preferential prices (negotiated by WHO and partners)

## Country/project


- Planning
- Logistics and distribution
- Implementation
- Reporting

## GDF

- Management of procurement orders
- Quality control (with IDA)
- Market review, forecasting

## IDA

- Purchasing
- Order consolidation
- Delivery to the country



# 2LDs available through the GLC mechanism

Drugs	Dosage	Pack size	Cost per pack	Cost per unit	Manufacturer
Capreomycin, powder for inj.	1 gr vial	1	1.027	1.027	Eli Lilly*
Capreomycin, powder for inj.	1 gr vial	1	3.25	3.21	Eli Lilly
Kanamycin, powder for inj.	1 gr vial	50	18.45	0.369	Panpharma
Cycloserin	250 mg cap	100	50.50	0.505	Macleods
Cycloserin	250 mg cap	100	14.45	0.1445	Eli Lilly*
Ethionamide	250 mg tab	100	10.10	0.101	Macleods
Protionamide	250 mg tab	100	12.50	0.125	Fatol
Ofloxacin	200 mg tab	100	3.80	0.038	Brown Burke
PASER	4 gr granules	30	47.64	1.588	Jacobus

Eli Lilly\* : limited quantity per year concessional price

# Constraints: medicines related

- **Shelf-life of medicines** (cycloserin 18m, capreomycin 24m)
- **Cold-chain needed for PASER** (Jacobus)
- **Production** (high risk due to the price+shelf-life, lack of interest from pharmaceuticals to the tight market, undeveloped manufacturing capacities)
- **Side effect profiles of some 2LD**

# Constraints: procurement related

- **Need of order consolidation** (due to variable times of delivery by different manufacturers)
- **No buffer stock** (to be established in 2007)
- **Lead times** (average 4 months from firm order and payment transfer)
- **Miscellaneous** (labelling, registration, customs regulations, procurement contracts requested by country partners)

# Constraints: treatment + project related

---

- Pace of enrolment

(not all patients are enrolled on the first day)

- Lengthy treatment

- More frequent treatment changes

(in comparison to first-line regimens) Most of the times due to adverse effects or changing resistance pattern

# Total order and incremental orders

---

- Total order can not be procured in one batch
- Total order approved represents a limit set by the application
- Incremental orders to be managed by the project directly with procurement agent
- Ordering annually or every semester

# New vs. ongoing project

---

- No management history to support estimation
- Baseline resistance patterns
- No experience, limited data on adverse effects in the patients population
- No data on outcomes, especially death, default, transfer rates

# Estimation tool

## Facilitates:

- Estimation of needs
- Budget preparation

## Takes into account:

- Prices of drugs available through the GLC mechanism
- Pace of patients' enrolment
- Treatment duration

# Estimation tool - demonstration

File Edit View Insert Format Tools Data Window WHOMenu Help

## WHO - StopTB

### SLD Estimation and Request Tool

Country:

**MENU**

- >> Please select an option below:
  - Prices of Drugs
  - Selection of Drugs
  - Patients Enrolment
- >> Reports Available:
  - Select from list....
  - No Reports Available
- >> Contact Us

**INSTRUCTIONS**

1. Select or type in the **Country** above
2. Click on **Selection of Drugs**
3. Enter planned **years of enrollment** below and planned duration of the intensive (with injectable) and continuation phases of treatment
4. Click on **Create Input Grid** and enter patients' enrollment rate
5. Click on **Update**
6. Select report for one of the years or the report for the total duration of the project, click **GO**.

**Years of Enrollment**    
(months)

**Duration in Months**

Phase 1 Treatment  (min 6 & max 14)  
Phase 2 Treatment  (min 12 & max 36)

Total Number of Patients:  
Total Years Funded:  
Total Months of Treatment:

## Total Request

Medicament (unit)	TOTAL UNITS	TOTAL PRICE
Capreomycin (1 gr vial)	7200	\$ 23,400
Cycloserin (250 mg tab)	149760	\$ 75,629
Ethionamide (250 mg tab)	74880	\$ 7,563
Kanamycin (1 gr vial)	5280	\$ 1,948
Ofloxacin (200 mg cap)	199680	\$ 7,588
PASER (4 gr sachets)	49920	\$ 79,273
Prothionamide (250 mg tab)	74880	\$ 9,360
<b>Total (USD)</b>		<b>\$ 204,761</b>

<i>Total Patients</i>	<b>80</b>
<i>Years of Enrolment</i>	<b>1</b>
<i>Years Required of Funding</i>	<b>3</b>
<i>Months of Treatment</i>	<b>36</b>